F E Davies
Overview
Explore the profile of F E Davies including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
2328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giles H, Drayson M, Kishore B, Pawlyn C, Kaiser M, Cook G, et al.
Blood Cancer J
. 2024 Mar;
14(1):50.
PMID: 38499538
Deeper responses are associated with improved survival in patients being treated for myeloma. However, the sensitivity of the current blood-based assays is limited. Historical studies suggested that normalisation of the...
2.
Jones J, Barber A, Le Bihan Y, Weinhold N, Ashby C, Walker B, et al.
Leukemia
. 2021 Aug;
35(10):3017-3020.
PMID: 34373585
No abstract available.
3.
Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell C, et al.
Leukemia
. 2018 Dec;
33(7):1713-1722.
PMID: 30573775
The iliac crest is the sampling site for minimal residual disease (MRD) monitoring in multiple myeloma (MM). However, the disease distribution is often heterogeneous, and imaging can be used to...
4.
Rasche L, Chavan S, Stephens O, Patel P, Tytarenko R, Ashby C, et al.
Nat Commun
. 2017 Aug;
8(1):268.
PMID: 28814763
In multiple myeloma malignant plasma cells expand within the bone marrow. Since this site is well-perfused, a rapid dissemination of "fitter" clones may be anticipated. However, an imbalanced distribution of...
5.
Went M, Sud A, Law P, Johnson D, Weinhold N, Forsti A, et al.
Blood Cancer J
. 2017 Jun;
7(6):e573.
PMID: 28622301
No abstract available.
6.
Shah V, Sherborne A, Walker B, Johnson D, Boyle E, Ellis S, et al.
Leukemia
. 2017 Jun;
32(1):102-110.
PMID: 28584253
Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent genetic aberrations is required as outcomes are variable despite apparent similar staging. We assayed copy number alterations...
7.
Pawlyn C, Bright M, Buros A, Stein C, Walters Z, Aronson L, et al.
Blood Cancer J
. 2017 Apr;
7(3):e549.
PMID: 28362441
Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for...
8.
Chavan S, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, et al.
Blood Cancer J
. 2017 Feb;
7(2):e535.
PMID: 28234347
The purpose of this study is to identify prognostic markers and treatment targets using a clinically certified sequencing panel in multiple myeloma. We performed targeted sequencing of 578 individuals with...
9.
Jones J, Cairns D, Gregory W, Collett C, Pawlyn C, Sigsworth R, et al.
Blood Cancer J
. 2016 Dec;
6(12):e506.
PMID: 27935580
We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here...
10.
Sawyer J, Tian E, Shaughnessy Jr J, Epstein J, Swanson C, Stangeby C, et al.
Leukemia
. 2016 Oct;
31(3):637-644.
PMID: 27694925
Hyperhaploid clones (24-34 chromosomes) were identified in 33 patients with multiple myeloma (MM), demonstrating a novel numerical cytogenetic subgroup. Strikingly, all hyperhaploid karyotypes were found to harbor monosomy 17p, the...